Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with MDD without psychotic features who had not responded to at least one adequate antidepressant trial, IV ketamine 0.5 mg/kg did not increase plasma BDNF levels 230 min after infusion.
“another study of patients with MDD without psychotic features who had not responded to at least one adequate antidepressant trial and who received intravenous ketamine at 0.5 mg/kg found no increase in plasma BDNF levels 230 min after infusion [98].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308 · cited 3× · see citing works
“Blood levels of BDNF and VEGF may not correlate with their concentrations in brain (Levy et al., 2018).”
BackgroundInfluentialDeyama, S., Bang, E., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.014 · Cited by 116 · see citing works
Flagged first, then by citations
Research works printed but not linked: 8
- Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, 2015. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord 186, 306– 311. 26275358
- Grunebaum MF, Ellis SP, Keilp JG, Moitra VK, Cooper TB, Marver JE, Burke AK, Milak MS, Sublette ME, Oquendo MA, 2017. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord 19, 176– 183. 28452409
- Haile C, Murrough J, Iosifescu D, Chang L, Al Jurdi R, Foulkes A, Iqbal S, Mahoney J III, De La Garza R, Charney D, 2014. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17, 331– 336. 24103211 PMC3992942
- Kadriu B, Ballard ED, Henter ID, Murata S, Gerlus N, Zarate CA Jr, 2020. Neurobiological biomarkers of response to ketamine. Adv Pharmacol 89, 195– 235. 32616207 PMC7681912
- Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr, 2009. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 70, 1662. 19744406 PMC2819547
- McGrory CL, Ryan KM, Gallagher B, McLoughlin DM, 2020. Vascular endothelial growth factor and pigment epithelial-derived factor in the peripheral response to ketamine. J Affect Disord 273, 380– 383. 32560932
- Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA, 2019. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry 24, 1040– 1052. 29487402 PMC6111001
- Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A, 2013. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol 28, 87– 90. 23124710
Cited by
Sorted by citations
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77 · see citing works
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75 · see citing works
Self-citationPardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51 · see citing works
Zheng, W., Gu, L.-M., Zhou, Y.-L., Wang, C.-Y., Lan, X.-F., Zhang, B., Shi, H.-S., Wang, D.-F., & Ning, Y.-P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780975 · Cited by 12 · see citing works
- Authors
- Medeiros, G. C., Greenstein, D., Kadriu, B., Yuan, P., Park, L. T., Gould, T. D., & Zarate, C. A.
- Affiliations
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 280
- Issue
- Pt A
- Pages
- 136-139
- ISSN
- 0165-0327 (ISSN-L)
- PMC
- PMC8194375
- OpenAlex
- W3104178670
- Cited by
- 24
- References
- 2
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 1 · 2022: 8 · 2021: 6
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Affective Disorders (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01BX004062, I01 BX003631)
- National Institutes of Health
- National Institute of Mental Health (R01MH107615, ZIAMH002857)
- National Institute of Allergy and Infectious Diseases (R21AI145211)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, depression, brain-derived neurotrophic factor, vascular endothelial growth factor, plasma biomarkers, neuroplasticity, antidepressant treatment
- MeSH terms
- Depression, Humans, Ketamine, Plasma, Brain-Derived Neurotrophic Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
